Zelira Therapeutics Limited (ZLD.AX)

AUD 0.62

(1.64%)

Market Cap (In AUD)

7.03 Million

Revenue (In AUD)

94.95 Thousand

Net Income (In AUD)

-36.56 Million

Avg. Volume

7387.00

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.28-1.09
PE
-
EPS
-
Beta Value
0.879
ISIN
AU000000ZLD1
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Oludare Odumosu
Employee Count
-
Website
https://www.zeliratx.com
Ipo Date
2003-07-25
Details
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company also provides OTC products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as ITURA, an advanced relief cream formula that targets multi-symptoms, such as numbness and tingling, muscle cramps, insensitivities, and pain associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; and the Children's Hospital of Philadelphia. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.